Comparing neuropsychological tasks to optimize brief cognitive batteries for brain tumor clinical trials

Neuropsychological tests are increasingly being used as outcome measures in clinical trials of brain tumor therapies. This study informs development of brief neurocognitive batteries for clinical trials by identifying cognitive tasks that detect effects on a group level in a mixed brain tumor popula...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuro-oncology 2010, Vol.96 (2), p.271-276
Main Authors: Lageman, Sarah K., Cerhan, Jane H., Locke, Dona E. C., Anderson, S. Keith, Wu, Wenting, Brown, Paul D.
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Agents, Alkylating - pharmacology
Antineoplastic Agents, Alkylating - therapeutic use
Attention - drug effects
Attention - physiology
Brain Neoplasms - complications
Brain Neoplasms - drug therapy
Clinical Study - Patient Study
Cognition Disorders - diagnosis
Cognition Disorders - etiology
Dacarbazine - analogs & derivatives
Dacarbazine - pharmacology
Dacarbazine - therapeutic use
Female
Humans
Language
Male
Medicine
Medicine & Public Health
Memory - drug effects
Memory - physiology
Middle Aged
Neurology
Neuropsychological Tests
Oncology
Retrospective Studies
Space Perception - drug effects
Space Perception - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neuropsychological tests are increasingly being used as outcome measures in clinical trials of brain tumor therapies. This study informs development of brief neurocognitive batteries for clinical trials by identifying cognitive tasks that detect effects on a group level in a mixed brain tumor population. This is a retrospective study of brain tumor patients who completed a standardized battery sampling multiple cognitive domains using twelve subtests with widely-used task formats (the Repeatable Battery for the Assessment of Neuropsychological Status). Sixty-eight patients with brain tumors were studied (60% high-grade glioma). Forty patients (58.8%) were impaired (>2 standard deviations below published means) on at least one subtest. A combination of four subtests (Figure Copy, Coding, List Recognition, and Story Recall) captured 90% of the impaired subgroup. These results suggest visuoconstruction, processing speed, and verbal memory measures may be the most important domains to assess when evaluating cognitive change in brain tumor clinical trials.
ISSN:0167-594X
1573-7373
DOI:10.1007/s11060-009-9960-y